Glucose Tolerance in the Proximal Versus the Distal Small Bowel in Wistar Rats
- 96 Downloads
- 6 Citations
Abstract
Background
Type 2 diabetes is an epidemic and insulin resistance is the central etiology of this disease. Obesity increases insulin resistance and glucose intolerance and also exacerbates metabolic abnormalities present in type 2 diabetes. Bariatric surgery is the most effective treatment for severe obesity. Most reported series show that return to euglycemia and normal insulin levels occur days after gastric bypass and biliopancreatic diversion, long before major weight loss has taken place. The mechanisms underlying this dramatic reversal of type 2 diabetes following these bariatric procedures are not well understood.
Methods
Twelve Wistar rats were fed with a palatable hyperlipidic diet for 12 weeks. Body weight, glucose, and intraperitoneal glucose tolerance test were measured regularly. On day 91, they were randomized in two groups (hindgut and controls) and operated. Twenty-one days later, the tests were done again and the hindgut group re-operated. A duodenal exclusion was done. The results of an intraperitoneal glucose tolerance test were compared after the procedures.
Results
Body weight increased regularly in all the rats. Some rats developed hyperglycemia 28 days after beginning hyperlipidic diet, but these levels returned to baseline on days 56 and 84. The glucose tolerance test showed an improvement in glycemic levels in the hindgut group 21 days after the first operation (151 ± 21mg/dl). After the second operation, despite weight loss, the glucose tolerance test of the foregut group worsened again (267 ± 53 mg/dl) (p < 0.01).
Conclusion
Comparing the “hindgut hypothesis” and the “foregut hypothesis”, our data show an improvement in the 30 min glucose tolerance test in the hindgut group.
Keywords
Diabetes mellitus Rats, Wistar Glucose intolerance Intestine, smallReferences
- 1.Venkat Narayan KM, Gregg EW, Fagot-Campagna A, et al. Diabetes:a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract. 2000;50(Suppl 2):S77–84.CrossRefGoogle Scholar
- 2.Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metabol Clin. 2003;32(4):805–22.CrossRefGoogle Scholar
- 3.Albu J, Pi-Sunyer FX. Obesity and diabetes. In: Bray GA, Bouchard C, James WPT, editors. Handbook of obesity. New York: Marcel Dekker; 1998. p. 697–707.Google Scholar
- 4.Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US:1990–1998. Diabetes Care. 2000;23:1278–83.CrossRefGoogle Scholar
- 5.Reaven GM, Banting lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.CrossRefGoogle Scholar
- 6.Olefsky JM, Kolterman OG, Scarlett JÁ. Insulin action and resistance in obesity and noninsulin-dependent type 2 diabetes mellitus. Am J Physiol. 1982;243:E15–30.PubMedGoogle Scholar
- 7.Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care Clin Office Pract. 2003;30:465–91.CrossRefGoogle Scholar
- 8.Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus 1986;35:990–8.CrossRefGoogle Scholar
- 9.Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefGoogle Scholar
- 10.Colquitt J, Clegg A, Loveman E, et al. Surgery for morbid obesity. Cochrane Database Syst Rev. 2003;(2):CD003641.Google Scholar
- 11.Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–37.CrossRefGoogle Scholar
- 12.Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947–54.CrossRefGoogle Scholar
- 13.Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.CrossRefGoogle Scholar
- 14.Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.CrossRefGoogle Scholar
- 15.Pories WJ, Swanson MS, MacDonald KG, et al. Who would have tought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50.CrossRefGoogle Scholar
- 16.Hickey MS, Pories WJ, MacDonald KG, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998;227:637–44.CrossRefGoogle Scholar
- 17.Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608–15.CrossRefGoogle Scholar
- 18.Frezza EE. Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success? Obes Surg. 2004;14:999–1005.CrossRefGoogle Scholar
- 19.Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004;36:747–54.CrossRefGoogle Scholar
- 20.Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide 1 7–36: a physiological incretin in man. Lancet 1987;2:1300–04.CrossRefGoogle Scholar
- 21.Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149–58.CrossRefGoogle Scholar
- 22.Patriti A, Facchiano E, Annetti C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15:1258–64.CrossRefGoogle Scholar
- 23.Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg. 2001;25:527–31.CrossRefGoogle Scholar
- 24.Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.CrossRefGoogle Scholar
- 25.Estadella D, Oyama LM, Damaso AR, et al. Effect of palatable diet on lipid metabolism of sedentary and exercised rats. Nutrition 2004;20:218–24.CrossRefGoogle Scholar
- 26.Vivas LAM, Jamel N, Refinetti RA, et al. Anesthetic experimental device for small animal. Acta Cir Brás. 2007;22(3):229–33.CrossRefGoogle Scholar
- 27.Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose and beta-cell function in Goto-Kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 2007;142:74–85.CrossRefGoogle Scholar
- 28.Prada PO, Zecchin HG, Torsoni MA, et al. Western diet modulates insulin signaling, c-jun N-terminal kinase activity and insulin receptor substrate-1ser307 phosphorylation in a tissue-specific fashion. Endocrinol 2005;146:1576–87.CrossRefGoogle Scholar
- 29.Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a nonobese animal model of type 2 diabetes. Ann Surg. 2004;239:1–11.CrossRefGoogle Scholar
- 30.Pacheco D, Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto_kakizaki rats. Am J Surg. 2007;194:221–4.CrossRefGoogle Scholar
- 31.Mason EE. Ileal transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg. 1999;9:223–8.CrossRefGoogle Scholar